Fig. 1.

EZN4150 inhibits proliferation of human epidermal growth factor receptor-2 positive (HER2+) breast cancer cells. a, b SKBR3 cells were treated with the 5 μM EZN3046 (scrambled control locked nucleic acid antisense oligonucleotide (LNA-ASO)) or EZN4150 (p110α targeted LNA-ASO). a Proliferation was assessed on day 12 of treatment. b Lysates were prepared for immunoblot analysis on day 9. c, d BT474 cells were treated as shown in a and b. Cells were counted (c) or lysed for immunoblot analysis (d) after 10 days of treatment. e, f UACC893 cells were treated as shown in panels a and b. e Relative cell number was determined on day 16 of treatment by sulforhodamine B assay. f Cells were lysed for immunoblot analysis after 12 days of treatment. g, h ZR75.1 cells were treated with the 5 μM EZN3046 or EZN4150. g Relative proliferation was determined by quantifying DNA in each well after 12 days of treatment. h After 10 days of treatment, cells were lysed and analyzed by immunoblot analysis (*p <0.05, Student t test). Cl. Casp3 cleaved caspase 3